Yes agree, I’m reasonably familiar with the distinctions, ESPAC group in UK has recently presented some results for BR after pre op therapy, they used accepted NCCN criteria to define BR to ensure consistency. I think Panco study left it to sites to decide, therefore not standardised. The point of all this is company has made repeated statements that all the patients resected in trial were truly non- resectable, but I think that’s inaccurate. they’ve reported R0 before, they say 8 of the 10 resections were R0 but unless they do independent retro review of pre treatment CTs to see who was BR, who was unresectable (by an accepted standard like NCN) it’ll be difficult to answer your question about any R0 in truly unresectable cases. At present company seems to be reporting the entire cohort as unresectable LAPC, no mention of BR anywhere.
OSL Price at posting:
12.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)